Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component by Petrović, Nina et al.
1285
Arch. Biol. Sci., Belgrade, 67(4), 1285-1295, 2015 DOI:10.2298/ABS150327105P
MICRO RNA-21 EXPRESSION LEVELS IN INVASIVE BREAST CARCINOMA  
WITH A NON-INVASIVE COMPONENT
Nina Petrović1,*, Snežana Jovanović-Ćupić1, Goran Brajušković2, Silvana Lukić3, Jelena Roganović4, 
Milena Krajnović1 and Vesna Mandušić1 
1 University of Belgrade-Vinča Institute of Nuclear Sciences, Belgrade, Serbia 
2 Faculty of Biology, University of Belgrade, Belgrade, Serbia
3 Institute for Oncology and Radiology of Serbia, Belgrade, Serbia 
4 Department of Pharmacology, Faculty of Dentistry, University of Belgrade, Belgrade, Serbia
*Corresponding author: dragoninspiration@yahoo.com
Abstract: Invasive ductal carcinomas with a non-invasive component (IDC-DCIS) are classified as a group of invasive 
breast carcinomas, together with pure invasive ductal carcinomas of the breast (IDC). MicroRNA-21 (miR-21) has been 
characterized as a factor of breast cancer invasiveness, however the difference in miR-21 expression levels between IDC-
DCIS and pure IDC tumors and the correlations with standard diagnostic and prognostic parameters inside the IDC-DCIS 
group are unknown. Our aim was to determine if miR-21 had the ability to distinguish these two invasive breast cancer 
groups. Levels of miR-21 expression were measured by a stem-loop quantitative Real-Time PCR (RT-qPCR) method. 
Expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2) 
and proliferative index Ki-67 were evaluated by immunohistochemistry. IDC-DCIS tumors had significantly lower levels 
of miR-21 expression in grade 2 (P=0.003, Mann-Whitney U test), ER positive (P=0.025, Mann-Whitney U test) and PR 
positive tumors (P=0.024, Mann-Whitney U test) than pure IDCs. miR-21 levels showed a different pattern of expression 
in IDC-DCIS compared to IDC tumors, which is based on the difference in miR-21 expression between Her-2 negative and 
Her-2 positive IDC-DCIS tumors (P=0.030, Mann-Whitney U test) and high negative correlation of miR-21 levels with PR 
levels (ρ=-0.886, P=0.006, Spearman correlation). According to our results, IDC-DCIS breast carcinomas act in a different 
manner in pure IDC tumors with regard to the relations between miR-21 expression levels and the standard diagnostic and 
prognostic parameters, such as Her-2 status, ER and PR status and protein levels.
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INTRODUCTION
Ductal carcinoma in situ (DCIS) is a breast cancer 
disease characterized by the cells that proliferate in-
side the basement membrane comprised of myoepi-
thelial cells in the breast ducts (Virnig et al., 2010). 
In some cases, they accompany invasive forms of the 
disease. About 25.4% cases of invasive breast carci-
nomas are associated with a non-invasive component 
(Soliman et al., 2012), and 30-60% patients with IDC 
contain DCIS form (Dieterich et al., 2014).
Solitary DCIS forms are very difficult to detect in 
Serbia because of the insufficient sensitivity of mam-
mography to DCIS histology (Brem et al., 2007). Only 
one in 10-20 cases of diagnosed breast cancer con-
tains DCIS form (Verkooijen et al., 2003; Wong et 
al., 2010). 
IDC-DCIS are classified according to the current 
American Joint Committee on Cancer staging system 
in the group of invasive breast carcinomas, based on 
the presence of invasive form (Singletary, 2002). Some 
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studies have demonstrated that DCIS associated with 
invasive forms share similar genomic profiles to pure 
invasive forms (Iakovlev et al., 2008). Although pa-
tients with IDC-DCIS were classified together with 
pure IDC according to its invasiveness (Chagpar et al., 
2009), most researchers analyze IDC-DCIS and pure 
IDC samples together. However, IDC-DCIS tumors 
on the molecular level differ considerably from pure 
IDC tumors, as Castro et al. (2008) have pointed out.
Several researchers expect tumors containing 
both-IDC and DCIS components to develop a less 
aggressive phenotype (Wong et al., 2010). Others 
suggest that the presence of an in situ part does not 
influence patient prognosis at all (Castro et al., 2008). 
However, other researchers developed an opposite hy-
pothesis. Because of the diffuse nature of DCIS, after 
the breast-conserving surgeries, IDC-DCIS patients 
might have a greater chance for local recurrence than 
pure IDC patients, and also might have a worse prog-
nosis (Chagpar et al., 2009). 
As the invasiveness of a tumor is a preliminary 
process to metastasis, it is now in the focus of many 
studies. MicroRNA-21 has been shown to be a very 
powerful factor in breast cancer invasion (Yan et al., 
2008; Huang et al., 2009; Song et al., 2010; Tang et al., 
2012; Petrović et al., 2014a; Petrović et al., 2014b), 
but the expressional levels of miR-21 and its potential 
correlations with the clinical and pathological features 
in IDC-DCIS tumors have not been characterized yet. 
miR-21 is a 22-nucleotide-long epigenetic factor that 
silences gene expression by binding to the mRNAs of 
its target genes (Qi et al., 2009). MicroRNA-21 is an 
oncogenic regulatory element that blocks or delays 
transcription of tumor suppressor genes (Kim et al., 
2009; Pan et al., 2010). This small silencer of transla-
tion is engaged with six out of ten key moments in 
breast cancer development and progression: growth 
suppressor evasion, proliferative signaling mainte-
nance, resistance to cell death, tumor-promoting in-
flammation, induction of angiogenesis, and induction 
of invasion and metastasis (Hanahan and Weinberg, 
2011), by trapping five target-gene-mRNAs: TIMP3, 
PDCD4, PTEN, TPM1 and RECK (Yang et al., 2009; 
Buscaglia, 2011). 
The IDC-DCIS form of a breast cancer disease 
might be a transitional state between in situ and in-
vasive breast carcinomas (Pinder and Ellis, 2003). An 
IDC-DCIS tumor might occur de novo (Farabegoli et 
al., 2002; Patla et al., 2002), or it can arise as a result 
of genetic and epigenetic changes in normal and/or 
DCIS tissue (Velds et al., 2006; Wong et al., 2010). 
The tumor could also be the result of changes in the 
signaling pathways in neighboring cells of the tumor 
or normal tissue that will be transformed to malig-
nant (by paracrine regulation) (Polyak and Hu, 2005; 
Daniel et al., 2011). The association of miR-21 expres-
sion levels with standard diagnostic and prognostic 
parameters in these entities is still unknown. It is also 
unknown whether they act in a similar manner to 
their potential “pure invasive relatives” or the changes 
occur as the consequences of actions in different mo-
lecular pathways. 
In our previous study, we have shown that inva-
sive with non-invasive ER positive tumors have lower 
miR-21 expression than pure invasive tumors (ILC, 
IDC and mixed-ILC-IDC tumors) and higher than 
non-invasive ER+ tumors (Petrović et al., 2014a). We 
also found that invasive associated with non-invasive 
tumors had lower expression of miR-21 in the PR-
positive subgroup compared to both pure invasive 
and even non-invasive tumors. Therefore, further 
research into and characterization of these entities 
was necessary. We performed an additional study to 
examine their unusual behavior. 
Based on our previous research (Petrović et al., 
2014b) and according to miR-21 expression levels 
that were distributed between non-invasive and pure 
invasive breast cancers, we suggest that IDC-DCIS 
might represent transitional forms during breast can-
cer invasion and progression. We have continued in-
vestigating only IDC-DCIS cases to characterize their 
effect on miR-21 expression levels. In this study, we 
have compared i) the miR-21 expression levels of 12 
invasive associated with non-invasive breast carcino-
mas with 11 pure IDC tumors from the same groups 
based on standard diagnostic and prognostic breast 
cancer parameters; ii) the miR-21 expression levels 
within the group of IDC-DCIS tumors divided into 
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subgroups formed according to standard diagnostic 
and prognostic parameters of breast tumors, and iii) 
the miR-21 expression levels with DCIS contribution 
in IDC-DCIS breast carcinomas. 
Our basic assumption was that IDC-DCIS tumors 
differ from pure IDC breast carcinomas (although 
both groups are classified as invasive breast carcino-
mas) in miR-21 expression levels in groups formed 
according to standard diagnostic and prognostic 
parameters such as age at diagnosis, menstrual sta-
tus, size of a tumor, tumor grade, lymph node status, 
estrogen receptor (ER), progesterone receptor (PR), 
human epidermal growth factor receptor 2 (Her-2) 
and proliferation index Ki- 67. Our second assump-
tion (based on the experimentally confirmed role of 
miR-21 in the process of breast cancer invasion) was 
that miR-21 expression levels negatively correlate 
with DCIS contribution.
MATERIALS AND METHODS
Study subjects
During this research, we have analyzed 12 invasive 
breast cancer samples that contained non-invasive 
components in different percent from patients that 
had undergone surgery at the Institute for Oncology 
and Radiology of Serbia between June 2012 and May 
2013. We compared their miR-21 expression levels 
with 11 samples of pure invasive ductal carcinomas 
(selected according to similar diagnostic and prog-
nostic parameters to IDC-DCIS samples). 
Tumor samples were divided into two sections, 
and characterized immediately after surgery. Parts of 
the tissues with at least 75% of malignant cells were 
used for further molecular analysis and parts were 
fixed with formalin and embedded in paraffin for 
routine pathological and histological characterization, 
analysis, and archiving.
This study was approved by an Institutional Re-
view Board approval according to the National Health 
Regulation 5002/1-01, and informed consent from 
all the examined patients was obtained. Histologi-
cal type, histological and nuclear grade, lymph-node 
status were determined by two pathologists. ER, PR, 
Her-2 status and Ki-67 were evaluated by a standard 
scoring system to determine adequate post-operative 
therapy. IDC and DCIS ratios in IDC-DCIS entities 
were presented in percentage determined by the two 
pathologists. 
Breast cancer tissue and molecular analysis 
Immunohistochemistry
For estrogen receptor (ER) and progesterone recep-
tor (PR) protein level evaluation, rabbit and mouse 
monoclonal antibodies (RM-9101-S1, Thermo Fisher 
Scientific, Cheshire, UK, and M3569, Dako Copen-
hagen, Denmark, respectively) were used on 4-5-μm 
sections of formalin-fixed paraffin-embedded blocks. 
The evaluation of human epidermal growth factor re-
ceptor 2 (Her-2) status was performed with antibody 
rabbit-antihuman A0485, (Dako, Copenhagen, Den-
mark). Ki-67 proliferation index was characterized 
with RM9106-S1 (Thermo Fisher Scientific, Cheshire, 
UK). For ER and PR status, Her-2 expression was con-
sidered positive at 3+ by immunohistochemistry (IHC) 
and at >2 by IHC and positive by chromogenic in situ 
hybridization (CISH) if = 2 (2+) (Di Palma et al., 2006). 
Ki-67 levels were evaluated as the percentage of posi-
tively stained cells. After deparaffinization, rehydration 
and treatment with 3% H2O2 for 10 min, tissue slides 
were immersed in 10 mM of citrate buffer (pH 6) in a 
microwave oven for 25 min. Samples were cooled and 
washed in TBS, pH 7.4. Sections were incubated with 
the antibodies at 1:50 dilutions with Ab Diluent Buffer 
(Code No.S0809 Dako, Copenhagen, Denmark). Then, 
samples were treated with the TP-125-HL (Thermo 
Fisher Scientific, Cheshire, UK) ready-to-use polymer 
system. For the visualization, we used diaminobenzi-
dine. Brown nuclear staining in cells was scored ac-
cording standards from Leake (2000).
RNA extraction and purification
All tissue samples were stored at -80°C immediately 
after surgery. Fresh-frozen tissues of breast cancer 
samples were homogenized in liquid nitrogen for fur-
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ther RNA isolation. Total RNA was extracted from 
powdered tissues with TRI Reagent (Ambion, Fos-
ter City). After a 10-min incubation in TRI Reagent, 
0.2 ml of chloroform was added to each sample. The 
samples were centrifuged for 10 min at 14000 RPM 
(4°C) and RNA samples were precipitated with iso-
propanol. Then, the samples were centrifuged (14000 
RPM, 4°C) and the pellet was rinsed with 1 ml of 
70% ice-cold ethanol. The pellets were dissolved in 
100 μL DEPC-DW and incubated at 65°C for 10 min. 
Quantification of RNA samples was performed by 
Biospec-Nano (Shimadzu Corporation, Japan). The 
quality of RNA samples has been also confirmed by 
denaturizing 1% agarose gel electrophoresis. 
miR-21 reverse transcription and stem-loop  
qRT-PCR
The expression of mature hsa-miR-21 5p and RNU6B 
as endogenous control was measured with TaqMan® 
Assays (ID: 000397 and ID: 001093, respectively). For 
reverse transcription we used in TaqMan Micro RNA 
Reverse Transcription Kit components and the fol-
lowing thermal conditions: 16°C for 30 min, 42°C for 
30 min and 85°C for 5 min. Following the steps from 
the TaqMan® Small RNA Assays Protocol (Applied 
Biosystems, Foster City, CA), we performed reverse 
transcription. In the second step, we quantified RT-
qPCR amplicons with Applied Biosystems (Foster 
City, CA) specific TaqMan® miR-21 and RNU6B As-
says with the following thermal conditions: 95°C 10 
min and 95°C 15 s; 60°C 60 s for 40 cycles. 
MicroRNA-21 expression levels were present-
ed in relative units, and the expression level values 
were normalized to RNU6B (small nuclear endog-
enous control), and the samples were calibrated to 
the sample with the lowest relative expression (set 
as referent-1x sample). Relative quantity values were 
analyzed with 7500 System SDS software. We used 
the relative-quantity-Δ∆Ct method, with the equa-
tion: RQsample=2-(ΔCtsample-ΔCtcalibrator) (where RQsample rep-
resents relative quantity of sample, while ∆Ct = CtmiR-
21-CtRNU6B). 
Statistical analysis
DCIS involvement was presented by percents and 
miR-21 relative expression levels were character-
ized by their medians. We used the Mann-Whitney 
U non-parametric test to compare 2 independent 
groups of samples. For correlation analysis, we used 
Spearman’s. P values ≤0.050 were statistically signifi-
cant, while those between 0.1 and 0.05 were consid-
ered a statistical trend. For the calculations of P val-
ues, we used GraphPad Prism 5 software (GraphPad 
Software, Inc. CA). 
RESULTS
miR-21 expression levels in IDC-DCIS and IDC 
tumor groups
We detected a statistical trend in the difference in 
miR-21 expression levels between the group of IDC-
DCIS and pure IDC tumor samples (P=0.053, Mann-
Whitney U test). A statistically significant difference 
in miR-21 expression levels between IDC-DCIS and 
pure IDC samples did not appear in patients younger 
than 60 years, older than 60 years, postmenopausal 
patients. Ten IDC-DCIS tumors differed with high 
significance in miR-21 expression level from pure 
IDC grade 2 samples with P = 0.003 (Mann-Whitney 
U test, Table 1, Fig. 1A). In lymph node-positive and 
lymph node-negative tumors there was no statistically 
significant difference in miR-21 expression level be-
tween IDC-DCIS and IDC carcinomas according to 
the Mann-Whitney U test. All IDC-DCIS patients 
were postmenopausal with no difference in miR-21 
expression compared with postmenopausal patients 
with pure IDC tumors. In tumor samples with ER+ 
status, IDC-DCIS significantly differed from pure 
IDC tumor samples in miR-21 expression level with 
P=0.025 (Mann-Whitney U test, Table 1, Fig. 1B). In 
tumor samples with PR+ status, there was also a sta-
tistically significant difference between IDC-DCIS 
and pure IDC tumor samples in miRNA-21 expres-
sion levels (P=0.024, Mann-Whitney U test, Table 
1, Fig. 1C). In Her-2-negative tumors, we detected 
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a statistical trend towards increased levels of miR-21 
expression in pure IDC tumors compared with IDC-
DCIS tumor samples (P=0.059, Mann-Whitney U 
test, Table 1). In Her-2-positive breast carcinoma 
samples, a statistically significant difference between 
IDC-DCIS and pure IDC tumor samples was not 
found. In addition, there were no significant differ-
ences in tumors with Ki-67 ≤20% and tumors with 
Ki-67 >20% between IDC-DCIS and pure IDC tu-
mors.
Table 1. The difference in miR-21 relative expression levels between size-matched IDC-DCIS and IDC tumor samples
aRelative miR-21 expression levels
Diagnostic and prognostic 
parameters of breast tumors IDC-DCIS
bN Pure IDC N c,dP value
Age
≤ 60 50.817 (35.137-179.896) 4 239.382 (89.001-333.937) 8 P = 0.461
>60 50.895 (35.867-64.087) 6 90.459 (23.365-97.989) 3 P =0.548
Menstrual status
Postmenopausal 99.775 (86.448-113.363) 8 88.802 (39.053-164.623) 4 P = 0.683
Grade
2 50.817 (35.867-64.087) 10 141.412 (97.989-270.900) 6 P = 0.003
Lymph node status
Positive 61.777 (35.867-64.811) 6 95.479 (38.874-150.484) 6 P = 0.310
Negative 50.817 (42.323-122.854 ) 6 141. 412 (58.097-231.405) 5 P = 0.537
ER status
Positive 52.278 (35.867-64.268) 8 141.412 (87.121-231.405) 9 P = 0.025
PR status
Positive 50.895 (34.779-64.449) 8 141.412 (87.121-231.405) 9 P = 0.024
Her-2 status
Negative 39.095 (33.691-45.088) 4 95.479 (56.956-145.948) 8 P = 1
Positive 64.087 (58.737-314.074 ) 6 239.382 (89.001-333.937) 3 P = 0.059
Ki-67 index (%)
≤ 20 64.449 (59.467-122.854) 7 150.484 (85.093-262.923) 5 P = 0.429
> 20 42.323 (37.481-44.397) 3 83.782 (36.807-141.412) 6 P = 0.381
aRelative miR-21 expression with 25th-75th percentile in parentheses. bN-number of samples. cP values equal or less than 0.05 were considered significant 
according to the Mann-Whitney U test (between 2 groups). dP values less than 0.1 were considered a statistical trend. 
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Fig. 1. The difference in miR-21 expression levels between IDC-DCIS and pure IDC tumor samples in (A) grade 2 tumors; (B) ER posi-
tive subgroup; (C) PR positive subgroup. The values of miR-21 expression levels are shown in relative units, normalized to RNU6B and 
calibrated to the sample with lowest miR-21 expression. The plot shows interquartile range (boxes) contoured with 25-75% of median 
values. Middle line indicates the median value and the whiskers extended from the boxes represent the highest and the lowest values, i.e. 
non-outlier ranges. Statistically significant differences were considered for P<0.05 values.
1290
miR-21 expression levels in the IDC-DCIS tumor 
group
In the group of patients younger than 60 years, sig-
nificantly different levels of miR-21 were not detected 
when compared with the group of patients older than 
60 years. Statistically significantly higher miR-21 ex-
pression was found in Her-2-positive compared to 
Her-2-negative tumors with P=0.030 in the IDC-
DCIS samples (Mann-Whitney U test, Table 2, Fig. 
2A). Tumors with proliferative index Ki-67 ≤20% 
compared with Ki-67>20% tumors had a statistical 
trend towards higher miR-21 expression levels in the 
IDC-DCIS samples (P=0.024, Mann-Whitney U test 
Table 2, Fig. 2B). Significant correlation between miR-
21 expression level and the age of patients and tumor 
size was not found. MicroRNA-21 expression levels 
highly negatively correlated with PR status (ρ=-0.886, 
P=0.006, Spearman’s correlation), but showed no cor-
relation with ER, proliferation index expression levels 
(Ki-67%) (Table 3), nor with DCIS contribution in 
percentage (Table 4).
DCIS contribution in IDC-DCIS tumors
Interestingly, there were no statistically significant dif-
ferences in miR-21 expression between IDC-DCIS tu-
mors with ≤30% of DCIS component compared with 
IDC-DCIS that contained >30% DCIS. The distribu-
tion of DCIS in percentage positively correlated with 
tumor size, with a high correlation coefficient value, 
ρ=0.718 (P=0.015, Spearman’s correlation) (Table 3). 
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Table 2. The difference in miR-21 relative expression levels be-
tween groups of IDC-DCIS tumor samples formed according to 
standard diagnostic and prognostic parameters of breast tumors.
Diagnostic 
and prognostic 
parameters of tumors
aRelative miR-21 
expression in IDC-DCIS 
tumors
bN cP value
Age
≤ 60 50.817 (35.137-179.896) 4
P = 1
>60 50.895 (35.867-64.087) 6
dSize
≤ 2cm 42.323 (31.565 -167.952) 5
P = 0.530
> 2cm 59.467 (42.783-64.268) 7
Lymph node status
Negative 50.817 (42.323-122.854) 6
P = 0.937
Positive 61.777 (35.867-64.811) 6
ER status
Negative 201.554 (56.547-346.561) 2
P = 0.334
Positive 52.278 (35.867-64.811) 8
PR status
Negative 89.701 (50.870-234.707) 5
P = 0.283
Positive 39.095 (33.691-59.467) 7
Her-2 status
Negative 39.095 (33.691-45.088) 6
P = 0.030
Positive 64.087 (58.737-314.074 ) 4
Ki-67 index (%)
≤ 20 64.449 (59.467-122.854) 7
P = 0.024
> 20 42.323 (37.481-44.397) 3
DCIS contribution (%)
≤ 30 64.449 (50.895-213.049) 4
P = 0.109
> 30 50.817 (34.779-40.477) 8
aRelative miR-21 expression with 25th-75th percentile in parentheses. 
bN-number of samples. cP Values equal or less than 0.05 were considered 
significant according to the Mann-Whitney U test (between 2 groups). 
dMaximal tumor diameter. 
Fig. 2. The difference in miR-21 expression inside the IDC-DCIS 
tumor group divided according to (A) Her-2 status and (B) the 
values of Ki-67 proliferation index. The values of miR-21 expres-
sion levels are shown in relative units, normalized to RNU6B 
and calibrated to the sample with lowest miR-21 expression. The 
plot shows interquartile range (boxes) contoured with 25-75% of 
median values. Middle line indicates the median value and the 
whiskers extended from the boxes represent the highest and lowest 
values, i.e. non-outlier ranges. Statistically significant differences 
were considered for P<0.05 values.
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In our experiment, DCIS contribution in IDC-DCIS 
entities correlated neither with patient age, ER and PR 
status, nor with the percentage of proliferation index 
Ki-67 expression levels (Table 4).
DISCUSSION
IDC-DCIS are classified according to the American 
Joint Committee in Cancer staging system as pure 
invasive forms (Singletary, 2002). Some studies have 
demonstrated that DCIS associated with invasive 
forms share similar genomic profiles with pure DCIS 
(Iakovlev et al., 2008), but Catro et al. (2008) showed 
that IDC-DCIS tumors significantly differ from IDC 
breast cancers at the molecular level.
The concept and the idea of our approach derived 
from our previous research where we noticed an in-
teresting behavior of invasive breast carcinomas with 
non-invasive component in that they significantly 
differed from pure invasive forms according to miR-
21 expression in the groups formed according to ER, 
PR, grade 2, and K-67 ≤20%. However, in the first 
study, we analyzed all types of pure invasive carci-
nomas together (invasive lobular, ductal and mixed). 
In order to highlight the significance of these unique 
entities and to emphasize the potential influence of 
certain prognostic and diagnostic factors, via changes 
in miR-21 expression levels, we excluded all types of 
breast carcinoma (BC) that had originated from oth-
er than breast ducts. Additionally, we included only 
IDCs with similar sizes to IDC-DCIS. In this study, 
we increased the number of IDC-DCIS samples. The 
novelty of this work lies in the fact that no research to 
date, to the best of our knowledge, has analyzed the 
association of miR-21 expression levels with standard 
diagnostic and prognostic parameters inside the IDC-
DCIS group. In addition, no one has yet compared 
DCIS contribution (as a potential factor that might be 
related to BC invasion) with the factor of BC invasive-
ness such as miR-21.
We observed a statistical trend towards increased 
levels of miR-21 expression in 11 pure IDC samples 
compared with 12 IDC-DCIS tumors. In grade 2-IDC 
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Table 3. Correlation of miR-21 expression levels with standard 
diagnostic and prognostic parameters of tumors and DCIS con-
tribution.
Variables Number  of samples
Coefficient  
of correlation
aP value
Age 10 -0.353 0.387
Size 12 0 0.968
ER 10 -0.206 0.578
PR 10 -0.886 0.006
Ki-67 10 0.359 0.353
bDCIS % 12 -0.418 0.297
ER, estrogen receptor; PR, progesterone receptor; Ki-67, proliferation 
index. aP-values less than 0.05 were considered statistically significant. 
bContribution of DCIS component.
Table 4. Correlation of DCIS contribution in percentage with 
standard diagnostic and prognostic parameters of breast tumors.
Variables Number  of samples
Coefficient  
of correlation
aP value
Age 10 -0.089 0.785
Size 10 0.718 0.015
ER 10 0.344 0.283
PR 10 -0.082 0.797
Ki-67 10 -0.0289 0.924
ER, estrogen receptor; PR, progesterone receptor;  
Ki-67, proliferation index.
aP-values less than 0.05 were considered statistically significant. 
bContribution of DCIS component.
Table 4. Correlation of DCIS contribution in percentage with 
standard diagnostic and prognostic parameters of breast tumors.
Variables Number of samples
Coefficient of 
correlation
aP value
Age 10 -0.089 0.785
Size 10 0.718 0.015
ER 10 0.344 0.283
PR 10 -0.082 0.797
Ki-67 10 -0.0289 0.924
ER, estrogen receptor; PR, progesterone receptor; Ki-67, proliferation 
index.
aP-values less than 0.05 were considered statistically significant. bContri-
bution of DCIS component.
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and IDC-DCIS tumors, the statistically significant 
difference appeared to be very high (with low P 
value). When we compared high miR-21 IDC-DCIS 
with high miR-21 IDC (according to their median 
ranges), we observed that the IDC tumors have sig-
nificantly higher miR-21 levels, whereas samples with 
low miR-21 levels did not differentiate between IDC-
DCIS and IDC samples. Additionally, this might be 
a special target group: high miR-21-IDC-DCIS or 
IDC-grade 2 group for future stratification and clas-
sification of breast carcinoma patients.
MicroR-21 expression levels found in IDC-DCIS 
tumors did not correlate with ER status, which is un-
usual, because in the group of pure invasive tumors, 
levels of miR-21 expression correlated highly posi-
tively with the levels of ER expression, which was also 
shown by Petrović et al. (2014a). In addition, ER+ 
and PR+ IDC-DCIS significantly differed from IDC 
ER+ and PR+ tumors in miR-21 expression levels. 
Although it has been shown that miR-21 expression 
might be a process dependant on ER expression (Mat-
tie et al., 2006; Wickramasinghe et al., 2009; Petrović 
et al., 2014a), in IDC-DCIS tumors, this might not 
be the case.
As we expected, a difference in miR-21 expres-
sion levels in PR+ patients appeared between the 
IDC-DCIS and IDC tumor groups, which indicates 
that higher miR-21 expression also might not be in-
ducted by increased levels of progesterone receptor. 
Surprisingly, the miR-21 levels of IDC-DCIS tumors 
highly negatively correlated with PR status, while 
pure invasive BCs from our previous study (Petrović 
et al., 2014a) highly positively correlated with PR lev-
els. The fact that miR-21 levels do not correlate with 
age, while in pure invasive they correlate negatively 
with the age of patients (Petrović et al., 2014b), could 
be due to the absence of ER/PR regulation of miR-21 
expression in IDC-DCIS tumor specimens because of 
the differences in hormonal status related to patient 
age (Ma et al., 2006). In IDC-DCIS tumors, Her-2 
positive tumors had significantly higher levels of miR-
21 expression, while pure invasive (IDC and ILC) tu-
mors acted independently from Her-2 status in the 
previous analysis (Petrović et al., 2014a). Huang et 
al. (2009) described Her-2-dependent miR-21 expres-
sion. We have also found that IDC-DCIS tumors do 
not have ER- and/or PR-dependant miR-21 expres-
sion, so these cases of multi-component tumors might 
have Her-2-dependant expression of miR-21, which 
supports our finding that there was significance in the 
difference of miR-21 expression levels between Her-
2-negative and Her-2-positive tumors. We detected 
significant difference in miR-21 expression levels 
between IDC-DCIS and IDC Her-2-positive tumors. 
This means that the Her-2 receptor is another factor 
that separates IDC-DCIS and IDC tumors with regard 
to miR-21 expression (Huang et al., 2009). Ki-67 is a 
marker of a tumor activity. Higher Ki-67 levels might 
indicate potential progression from non-invasive to-
wards aggressively invasive phenotype (Gerdes et al., 
1991). Elevated Ki-67 levels in DCIS tumors might 
anticipate recurrence of the in situ carcinoma after 
breast-conserving surgery or progression to IDC. 
Wong et al. (2010) showed that the frequency of IDC-
DCIS was associated with Ki-67 levels in a low Ki-67 
group. We did not find statistically significant differ-
ences between miR-21 levels in IDC-DCIS and IDC 
groups when divided into tumors with Ki-67≤20% 
and Ki-67>20%. In the IDC-DCIS tumor group, we 
observed that tumors with Ki-67≤20 had significantly 
higher miR-21 expression levels than Ki-67>20 tu-
mors, similar to pure invasive tumors from our previ-
ous study, (Petrović et al., 2014a). Our findings could 
be explained by the dual form of the tumor, i.e. the 
influences of both-DCIS and IDC components that 
are individual. Wong et al. (2010) implied in their re-
search similar findings. We assumed that the presence 
of DCIS might not be silent, and might have some 
impact based on the changes in genetic and epigen-
etic levels that might have some repercussion on the 
behavior of the entire tumor (Chagpar et al., 2009). 
However, our findings showed that there were no re-
lations between miR-21 expression levels and DCIS 
contribution. Furthermore, we compared IDC-DCIS 
tumors with less than or equal to 30% of DCIS with 
tumors containing more than 30% of DCIS, and there 
was a lack of significant difference. DCIS % highly 
positively correlated with tumor size, but correla-
tions with age, ER, PR or Ki-67 were not found. Also, 
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miR-21 expression does not depend on the histologi-
cal type of a tumor (whether we compare IDC-DCIS 
with IDC, with ILC, or ILC and IDC together) ac-
cording to the results of previous and present studies 
(Petrović et al., 2014a; Petrović et al., 2014b).
The question whether these are transitional forms 
between in situ and invasive tumors is impossible to 
answer, because each person is unique and breast 
cancer is a very heterogeneous disease, influenced 
by many genetic, epigenetic and microenvironmen-
tal factors (Allinen et al., 2004; Polyak and Hu, 2005; 
Polyak, 2007). 
In our previous research (Petrović et al., 2014a) we 
implied that it was necessary to add new non-standard 
diagnostic and prognostic markers and that it was also 
necessary to form additional systems of classification 
and therapeutic approach. New therapy approaches 
should be used especially in ER+/PR+ and ER+/
PR- groups of patients with higher miR-21 expres-
sion levels, in order to prevent or halt further inva-
sion and metastases in patients that do not respond or 
are resistant to tamoxifen. It has already been shown 
that miR-21 expression was related to ER expression 
(Wickramasinghe et al., 2009; Yan et al., 2011). Also, 
miR-21 expression levels in ER+/PR+, ER+PR- or 
ER-/PR- subgroups of patients with invasive BCs as-
sociated with non-invasive should be considered to 
act differently. These findings confirm our assumption 
that invasive cancers with non-invasive breast cancer 
forms act in a different manner when compared to 
pure invasive tumors according to miR-21 expression 
levels. In addition, based on our findings related to 
the different behavior of miR-21/ER/PR/Her-2 factors, 
high- miR-21/ER+/PR+/PR-/grade 2 and/or Her-2+ 
IDC-DCIS tumors might have therapeutically chal-
lenging phenotype for future anti-miR therapies.
MicroRNA-21 expression in IDC-DCIS tumors 
that were investigated might have been Her-2-depen-
dant; this could have been responsible for the differ-
ence in miR-21 expression between Her-2- and Her-
2+ subgroups (that was not detected in pure invasive 
tumors) (Huang et al., 2009; Petrović et al., 2014a; 
Petrović et al., 2014b). Thus, Her-2+ groups with 
higher miR-21 expression levels in patients that do 
not respond to conventional therapies with herceptin 
should be considered for future anti-miR-21 therapy 
(in contrast to pure invasive breast carcinomas, ac-
cording to our study). 
In summary, in the previous research we showed 
that miR-21 expression in groups formed according 
to ER, PR, grade 2 and K-67≤20% significantly dif-
fered from those in pure invasive forms, while in our 
novel research (with fewer factors included and with 
a slightly larger IDC-DCIS group), these two groups 
differed with higher significance in our present re-
search, and differed in Her-2-positive tumors, unlike 
in our previous research (Petrović et al., 2014b). Also 
in this study, the difference in K-67≤20% group did 
appear, unlike previous results (Petrović et al., 2014b).
CONCLUSIONS
This study shows the complexity and heterogeneity of 
breast cancer and the need for additional systems of 
classification as well as the need to identify new fac-
tors/biomarkers. In order to improve access to treat-
ment and therapy, multi-component tumors should 
be considered as special entities. It is necessary to seek 
new ways of treatment and to move towards a per-
sonalized and away from a generalized approach to 
patients with breast carcinoma.
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